FACTOR IX CONCENTRATE (RECOMBINANT)

(BeneFIX®; rFIX)

CLASSIFICATION

- Coagulation factor.

INDICATIONS

- Prevention and control of bleeding episodes caused by factor IX deficiency, also known as Hemophilia B or Christmas disease.

ADMINISTRATION

- Prior to reconstitution, bring diluent and concentrate to room temp. Do not exceed 37°C. Reconstitute according to manufacturer's instructions.
- IV direct: physician or RHCP; over several minutes (rate determined by patient's comfort level).

POTENTIAL ADMINISTRATION HAZARDS

- Hypersensitivity: rash, urticaria, chills (rigors), flushing, angioedema, dyspnea, wheezing, tachycardia, hypotension, anaphylaxis.
- GI: nausea, abnormal taste.
- CNS: headache, dizziness.
- Local reactions: pain or burning along injection site, phlebitis.

DOSAGE

- Individualized depending upon degree of deficiency, the desired level of deficient factor, weight of patient and severity of bleeding.
- Should be based on coagulation studies performed prior to surgery and at regular intervals during treatment.
- Units required: body weight (kg) X 1.2 unit/kg X desired factor IX increase (in % of normal).
- For specific dosing recommendations, consult manufacturer's information.

COMPATIBILITY, STABILITY

- Store Benefix® at room temp or refrigerated (2-30°C).
- Following reconstitution, use within 3 hours to avoid bacterial contamination. Do not refrigerate reconstituted solution.

MISCELLANEOUS

- Contraindicated in patients with a known history of hypersensitivity to hamster protein.
- One international unit of Factor IX corresponds to the activity of Factor IX present in 1 mL of fresh normal plasma.

AVAILABILITY

- Factor IX concentrate (recombinant) is available from the Blood Bank

REFERENCES

1, 2, 5, 40, 95

2015 (KGH Revision Nov 2017)